Ipriflavone (Osteofix)

製品コードS2422 バッチS242202

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C18H16O3
分子量 280.32 CAS No. 35212-22-7
Solubility (25°C)* 体外 DMSO 56 mg/mL (199.77 mM)
Ethanol 2 mg/mL (7.13 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Ipriflavone (7-Isopropoxyisoflavon) is used to inhibit bone resorption.
in vitro Ipriflavone regulates the differentiation and biosynthetic properties of human bone marrow stromal osteoprogenitor cells (BMC) by enhancing the expression of some important matrix proteins and facilitating the mineralization process. [1] Ipriflavone treatment at 10 μM significantly inhibits advanced glycation end products (AGE) enhanced bone resorption in cultured mouse unfractionated bone cells. [2] In addition, Ipriflavone treatment potently enhances calcium uptake by duodenal cells. [3] Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells in a dose-dependent manner, and blocks the ligand-induced phosphorylation of Tyr845 of the EGFR. Ipriflavone treatment at 50 μM does not induce apoptosis of MDA-231 cells. [4]
in vivo Oral administration of Ipriflavone at 12 mg but not 6 mg significantly inhibits the development of new osteolytic bone metastases of MDA-231 cells, suppresses the progression of established osteolytic lesions, and reduces the number of osteoclasts adjacent to cancer cells in bone metastases. Consistent with the in vitro activity, Ipriflavone treatment at 6 or 12 mg/day significantly inhibits tumor growth of MDA-231 xenografts with 25% and 45% reductions by volume and 47% and 63% by weight, respectively, compared to untreated mice, and prolongs the life of tumor-bearing mice. [4] LD50: Mice >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.); Rats >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.) [5]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 MDA-231 cells
濃度 Dissolved in absolute ethanol, final concentrations ~50 μM
反応時間 24, 48, 72 and 96 hours
実験の流れ Cells are exposed to various concentrations of Ipriflavone for 24, 48, 72 and 96 hours. Cells are treated with trypan blue to estimate the number of viable cells. For thymidine incorporation analysis, [3H]Thymidine (1 μCi) is added, and cells are harvested onto glass fiber filters 4 hours later. Radioactivity is determined by scintillation counting.
動物実験 動物モデル Male athymic nude mice (ICR-nu/nu) injected s.c. or intracardially with MDA-231 human breast cancer cells
投薬量 ~12 mg/day
投与方法 Oral administration

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。